3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
91
Neoplasm Metastasis
24
Neoplasms
14
Brain Neoplasms
13
Prostatic Neoplasms
10
Endometrial Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Ovarian Neoplasms
7
Glioblastoma
7
Glioma
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Sarcoma
4
Recurrence
4
Pancreatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Sarcoma, Ewing
3
Osteosarcoma
3
Neoplasms by Site
3
Multiple Myeloma
3
Meningioma
3
Melanoma
3
Liposarcoma
3
Carcinoma, Renal Cell
3
Breast Diseases
3
Unilateral Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Interventions
Fluorouracil
67
Radiotherapy
53
Cisplatin
52
Oxaliplatin
47
Leucovorin
37
Paclitaxel
36
Irinotecan
27
Docetaxel
23
Capecitabine
20
Nivolumab
16
Carboplatin
16
pembrolizumab
15
Radiation
15
Neoadjuvant Therapy
15
Surgical Procedures, Operative
12
Cetuximab
12
durvalumab
9
Taxes
8
Folfox protocol
8
Drug Therapy
8
Chemotherapy, Adjuvant
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
7
Gefitinib
7
tremelimumab
6
Endoscopy, Digestive System
6
Endoscopy
6
Biopsy
6
Specimen Handling
5
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma Of Esophagus
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled